地奥心血康胶囊联合艾司洛尔治疗不稳定型心绞痛的疗效观察

目的研究地奥心血康胶囊联合盐酸艾司洛尔注射液治疗不稳定型心绞痛的临床疗效。方法选取2017年8月—2018年8月安徽省第二人民医院收治的120例不稳定型心绞痛患者作为研究对象,将所有患者采用随机数字表法分为两组,每组各60例。对照组患者给予盐酸艾司洛尔注射液,静脉注射负荷量0.5 mg/(kg?min),1 min后维持剂量为0.05 mg/(kg?min);治疗组在对照组的基础上口服地奥心血康胶囊,2粒/次,3次/d。两组患者持续治疗1周。观察两组患者的临床疗效和心电图疗效,同时比较两组治疗前后的临床症状和心功能指标水平。结果治疗后,对照组临床疗效和心电图疗效分别为81.67%、81.67%,分别显著低于治疗组的95.00%、95.00%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者心电图ST段位移、心绞痛持续时间和心绞痛发作频率均明显降低,同组治疗前后比较差异具有统计学意义(P0.05);治疗后,治疗组临床症状指标显著低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者心排出量(CO)、心脏指数(CI)和左室射血分数(LVEF)水平均显著高于治疗前,左室舒张末期容积(LEDV)和左室收缩末期容积(LESV)水平均显著降低,同组治疗前后比较差异具有统计学意义(P0.05);治疗后,治疗组心功能指标明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论地奥心血康胶囊联合盐酸艾司洛尔注射液治疗不稳定型心绞痛具有较好的临床疗效,能够显著改善心绞痛症状和心功能指标,安全性较高,具有一定的临床推广应用价值。

Clinical observation of Di'ao Xinxuekang Capsules combined with esmolol in treatment of unstable angina pectoris

Objective To study the clinical efficacy of Di''ao Xinxuekang Capsules combined with Esmolol Hydrochloride Injection in treatment of unstable angina pectoris. Methods Patients (120 cases) with unstable angina pectoris in Anhui Second People''s Hospital from August 2017 to August 2018 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Esmolol Hydrochloride Injection 0.5 mg/(kg∙min), maintenance dose of 0.05 mg/(kg·min) after 1 min. Patients in the treatment group were po administered with Di''ao Xinxuekang Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for one week. After treatment, the clinical efficacy and electrocardiogram efficacy were evaluated, and the clinical symptoms and cardiac function indicator levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and electrocardiogram efficacy in the control group were 81.67% and81.67%, which were significantly lower than 95.00% and 95.00% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, ST segment displacement of electrocardiogram, duration and attack frequency of angina pectoris in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the clinical symptom indicators in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CI, CO, and LVEF in two groups were significantly increased, but the levels of LEDV and LESV were decreased, the difference was statistically significant in the same group (P<0.05). After treatment, the cardiac function indicator levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05).Conclusion Di''ao Xinxuekang Capsules combined with Esmolol Hydrochloride Injection has a good clinical effect in treatment of unstable angina pectoris, can significantly improve the symptoms of angina pectoris and cardiac function indicators, with high safety, which has a certain clinical application value.